PM360

AUGUST 1, 2022

PM360’s 2022 December Innovations Issue Open for Submissions. NEW YORK, NY, August, 1, 2022 : Within the past couple of years, we have seen some of the greatest advancements ever made by the life sciences and healthcare industries. Senior Editor, PM360. 646-300-8113. andrew.matthius@pm360online.com.

Marketing 52

Marketing Healthcare Healthcare Education 52

PM360

AUGUST 24, 2023

Now, Real Chemistry is at the forefront of applying analytics, data, and artificial intelligence to the biopharma and healthcare industry and, in 2022, the company achieved its 21st consecutive year of double-digit growth. Dermavant Sun Pharmaceutical Industries Ltd. Braun Medical, Inc.

Marketing 52

Marketing Education Media Healthcare 52

PharmaKinnex

AUGUST 23, 2022

August 23, 2022. The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. Today, in 2022, the industry is changing again, and in some big, exciting ways. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve! dstansberry@costellocreativegroup.com.

Pharma 52

Pharma Sales Sales Strategy Marketing 52

PM360

AUGUST 17, 2022

PM360 Announces 2022 Trailblazer Award Finalists. NEW YORK, NY, August 17, 2022— PM360 has announced the finalists for its 14 th annual Trailblazer Awards. PHARMACEUTICAL/BIOTECH. Takeda Pharmaceutical Company. Avion Pharmaceuticals. DHIVY Marketing Team (Avion Pharmaceuticals and Agency Partner: Calcium).

Marketing 52

Marketing Healthcare Healthcare Education 52

European Pharmaceutical Review

NOVEMBER 11, 2022

The American Heart Association (AHA)’s Scientific Sessions 2022 is a global exchange of the latest advancements in research and clinical practice of cardiovascular science. Heart failure treated with first-in-human in vivo gene-editing therapy using CRISPR technology . August 2021. J Am Coll Cardiol. 2013;61(4):391–403.

Safety 109

Safety Medical Patients Transportation 109

Pharmaceutical Technology

NOVEMBER 15, 2022

However, a recent study in the Journal of American Medical Association suggests that Paxlovid may not be the sole cause for this relapse in Covid-19 symptoms. In the recent JAMA publication, Covid-19 symptoms were assessed for 29 days in untreated participants who received a placebo in the ACTIV-2/A5401 trial between August and November 2020.

Food and Drug Administration 64

Food and Drug Administration Government Distribution FDA 64